Reduced coagulability occurs during leukemia treatment, and platelets and other components can be transfused on the basis of leukemia treatment to improve coagulation function.
Due to the abnormal bone marrow hematopoietic function, leukemia is often accompanied by different degrees of decline in platelet levels at the onset of the disease, which is further aggravated by the effect of chemotherapy on the bone marrow hematopoietic function, and the degree of thrombocytopenia. A severe drop in platelet count can lead to impaired hemostasis, which in turn leads to abnormalities in coagulation.
Reduced platelet counts can be corrected by transfusion of plasma components such as single platelets to maintain platelet counts above 10 x 10^9/L to reduce the risk of spontaneous bleeding. If the poor coagulation function is caused by deficiency of coagulation factors, then fresh frozen plasma can be transfused.
Seek medical attention when leukemia is present and at the hospital. Transfusion of blood components should be performed under the supervision of a clinician, and should not be performed without authorization.